26 results about "Intestinal structure" patented technology

The invention provides a functional feed additive for relieving oxidative damage to intestinal tracts of piglets as well as a preparation method and application of the functional feed additive. The functional feed additive is prepared from the following components in parts by weight: 30 to 50 parts of plant extract, 0.5 to 2 parts of operculate cleistocalyx flower polyphenol-mesoporous silicon dioxide nanoparticles, 0.05 to 1 part of vitexin and 1 to 3 parts of sugarcane polyphenol. The product provided by the invention can relieve intestinal structure damage caused by oxidative stress of piglets and protect normal structures and functions of intestinal tracts; inflammatory factors are reduced, inflammatory response is improved, and intestinal health is maintained; the piglet diarrhea is reduced, and the production performance of piglets is improved.

The invention relates to a fermented traditional Chinese medicine composition for preventing and treating piglet viral diarrhea as well as a preparation method and application thereof, and relates to the technical field of livestock breeding. The feed is prepared by taking traditional Chinese medicine components as basic raw materials and adding probiotics for fermentation, and the traditional Chinese medicine components comprise the following raw materials in parts by weight: 0.5-1.5 parts of cardamine violifolia dry powder, 5-15 parts of Chinese pulsatilla root, 10-20 parts of coptis chinensis, 10-20 parts of golden cypress, 10-20 parts of ash bark, 4-8 parts of turmeric, 6-10 parts of pumpkin seeds and 4-8 parts of a ginkgo leaf extract feed additive. Through cooperation of multiple components, the immunity and antioxidant functions of the body are enhanced, the structural integrity of the intestinal tract is maintained, piglet diarrhea caused by PEDV infection is effectively relieved, and growth and development of the piglet are promoted; local specialty crops are selected as medicines, and theoretical basis and practical reference are provided for deep processing of local genuine medicinal materials and PED prevention and control.

The invention provides application of D-mannose in preparation of a product for improving intestinal mucosa immunity and / or intestinal flora homeostasis of weaned piglets, and particularly belongs to the technical field of weaned piglet breeding. The invention provides application of D-mannose in preparation of a product for improving intestinal mucosal immunity and / or intestinal flora homeostasis of weaned piglets. The D-mannose is derived from a natural plant, can stably and efficiently improve intestinal mucosa immunity and intestinal flora homeostasis of the weaned piglets, relieves diarrhea, and improves the growth performance of the weaned piglets at the same time. Specifically, D-mannose can improve the growth performance of weaned piglets, reduce the diarrhea rate, improve the intestinal structure, enhance the chemical barrier function of the intestinal tract, reduce the abundance of harmful bacteria in the intestinal tract and increase the content of short-chain fatty acid producing bacteria.

The application relates to application of iron-nitrogen doped graphene in preparation of anti-radioactive enteritis drugs and belongs to the technical field of biological medicines. ZIF-8 powder, 1,10-phenanthroline powder, iron (II) acetate powder and a grinding medium are placed in a closed container to perform mechanical ball milling treatment to obtain a mixed powder; under the protection of inert gas, the mixed powder is placed in a preheated tube furnace to perform pyrolysis treatment, and is cooled to room temperature to obtain iron-nitrogen doped graphene. The iron-nitrogen doped graphene has NADH oxidase-like activity, can directly catalyze the conversion of NADH into NAD + , can rapidly supplement NAD + depletion caused by radiation, can enhance PARP-dependent DNA damage repair, can reduce the generation of active oxygen (ROS), can reduce intestinal cell death and can protect the integrity of intestinal structure, and can realize efficient protection of radioactive enteritis. Moreover, the problem of low-efficiency biosynthesis of NAD + supplementation in existing radioactive intestinal injury protection technologies is solved.

This invention relates to the field of intelligent medical technology, and more particularly to a method for early warning of intestinal fibrosis in Crohn's disease based on a large model. The method includes: acquiring intestinal MRI image sequences of Crohn's disease patients; inputting the intestinal MRI image sequences into a pre-trained large model for intestinal structure analysis to locate the initial intestinal fibrosis region; determining whether the degree of intestinal luminal stenosis in Crohn's disease patients meets the standard based on the intestinal stenosis progression index, and adjusting the feature contrast threshold of the large model based on the difference; determining whether the acute inflammation masking effect of Crohn's disease patients is adequate based on intestinal wall edema characterization parameters, and adjusting the T2-weighted imaging modal weights of the large model based on the relative difference; and determining whether the patency of the fibrotic permeation channel in Crohn's disease patients is adequate based on the fibrotic permeation resistivity, and adjusting the boundary loss weights of the large model based on the ratio. This invention improves the accuracy of early warning of intestinal fibrosis in Crohn's disease.

The invention discloses application of retinaldehyde dehydrogenase activating peptides derived from three euphausia superba in prevention or treatment of radiotherapy intestinal side reactions, and belongs to the technical field of bioactive peptides. The euphausia superba-derived retinaldehyde dehydrogenase activating peptides have three kinds of amino acid sequences, and the amino acid sequences of the retinaldehyde dehydrogenase activating peptides are respectively shown as SEQ ID NO.1-3. The euphausia superba-derived retinaldehyde dehydrogenase activating peptide is applied to prevention or treatment of radiotherapy intestinal side reactions. According to the invention, three potential retinaldehyde dehydrogenase activated peptides are identified from the antarctic krill protein peptide sequence by using high-resolution mass spectrometry, and the effect of the retinaldehyde dehydrogenase activated peptides on preventing or treating radiotherapy intestinal side reactions is verified by using animal experiments. Results show that three small molecule peptides can improve weight loss and intestinal structure damage caused by radiation, thereby repairing intestinal mucosal barriers and improving side effects of radiotherapy intestinal tracts.

The invention provides a lysozyme-based quercetin colon-targeted nanoparticle as well as a preparation method and application of the lysozyme-based quercetin colon-targeted nanoparticle. According to the invention, a quercetin-Fe < 2 + > metal polyphenol network (MPN) nano core is constructed by a solvent exchange method, and then the quercetin-Fe < 2 + > metal polyphenol network (MPN) nano core, positively charged egg white lysozyme and negatively charged pectin are subjected to electrostatic self-assembly in sequence to form the nano particle with a triple coating structure. The encapsulation rate of quercetin in the nano-particles ranges from 77% to 98%, the drug loading rate ranges from 13% to 32.2%, and the nano-particles have excellent gastrointestinal stability and colon targeting. High-fat model animal experiment results show that the nanoparticles have good lipid-lowering effect and oxidation resistance, and can protect intestinal structures and functions. The problems of poor stability and insufficient targeting in oral delivery of quercetin are effectively solved, and a green and efficient solution is provided for colon targeting delivery of polyphenol functional factors.

The invention discloses polygalacturonic acid (PGA) and application of a neohesperidin dihydrochalcone (NHDC) or neohesperidin (NH) embedded compound of the polygalacturonic acid (PGA) in preparation of anti-allergic food or drugs. The PGA has good biocompatibility and immune regulation and intestinal barrier repair functions. Experiments show that the PGA can significantly reduce IgE-mediated food anaphylaxis, alleviate allergic symptoms and improve intestinal structures. PGA is adopted as a carrier, and the PGA and NHDC / NH form non-covalent binding through intermolecular force to prepare the PGA-NHDC / PGA-NH compound, so that the solubility and the stability of the NHDC / NH are improved, and a synergistic anti-allergic effect is also generated. The PGA-NHDC / PGA-NH compound has the advantages of small molecular weight, fast absorption and non-immunogenicity, and can release NHDC / NH in colon in a targeted manner. On the basis, the invention further provides the application of the PGA-NHDC / PGA-NH compound in preparation of the orange juice, the obtained juice system is in a stable suspension state, has no precipitation layering phenomenon, has targeted synergistic antianaphylaxis and high storage stability, and remarkably improves the functionality and the storage stability of the juice.

The invention relates to a probiotic composition and application thereof, and belongs to the technical field of compositions. Comprising Ackerman muciniphila ATCC BAA-835 and Bifidobacterium animalis subsp. Lactis BB-12, wherein the CFU (colony forming unit) ratio of the Ackerman muciniphila ATCC BAA-835 to the Bifidobacterium animalis subsp. Lactis BB-12 is 1 The two strains have a synergistic effect, and the prepared probiotic composition can synergistically relieve the phenomena of weight loss, colon shortening, intestinal structure and intestinal barrier injury, proinflammatory factor increase, anti-inflammatory factor reduction, intestinal flora and histidine metabolism disorder and the like of dextran sodium sulfate induced mouse ulcerative colitis. Therefore, the effect of preventing and relieving the severity of the inflammatory bowel disease is achieved.

The invention relates to the technical field of feed, in particular to application of inulin in improving the laying rate of laying hens and feed efficiency. The laying rate and the feed conversion efficiency are remarkably improved, the laying period is prolonged, meanwhile, the slaughter rate is improved, and the breeding cost is reduced; the eggshell color and structure are adjusted, the eggshell thickness and strength are improved, the egg yolk nutrition index is synchronously improved, and the market competitiveness is enhanced; the serum hormone level is adjusted, the immune response and antioxidant capacity are enhanced, oxidative stress injury is reduced, and the health of chicken flocks is guaranteed; skeletal development and mineral deposition are promoted, serum uric acid and triglyceride levels are adjusted, and metabolic diseases are prevented; the intestinal structure is optimized, the yield of short-chain fatty acid is increased, the content of unsaturated fatty acid in egg yolk is increased, and the flavor and nutritional value of the product are improved; the antibiotic dependence is reduced through a natural substitution mechanism, the trend of green breeding and food safety is met, and the sustainable development of the industry is promoted.

The invention discloses a method for detecting ovalbumin through an electrochemical bionic small intestine micro-fluidic chip sensor and application, and belongs to the technical field of food safety detection. A micro-intestinal chip is designed by simulating the structure of the small intestine of a human body, an anti-IL-6 antibody is integrated on a screen-printed electrode to serve as a specific recognition element, a sensor capable of being used for specifically recognizing cell secretion IL-6 is constructed, and effective and indirect measurement of OVA is achieved. An OVA standard substance is used for testing the bionic small intestine sensor, a good linear relation exists between the resistance value detected by an electrochemical means and the OVA concentration, the linear detection range is 0.2 pg / mL to 4 pg / mL, the detection limit is 0.161 pg / mL, and it is proved that the bionic small intestine sensing interface is feasible and the sensor can conduct quantitative sensitive detection on the allergen protein.

The invention provides an application of yolk immunoglobulin in preparation of a medicine for preventing and treating digestive tract inflammatory diseases, and belongs to the technical field of biological medicines. The egg yolk immunoglobulin is used for preventing and treating inflammatory diseases of digestive tracts, can relieve inflammatory response of the digestive tracts, inhibit disease progression, relieve hemafecia, diarrhea and tissue edema and hyperemia, and can also regulate the immune function of the intestinal tracts, enhance the barrier effect of intestinal mucosa, promote repair of damaged intestinal mucosa, improve the environment in the intestinal tracts from the source and improve the immunity of the intestinal tracts. The intestinal structure is complete, and the phenomenon of sparse villus in the intestinal tract is avoided. Moreover, the egg yolk immunoglobulin is derived from eggs, belongs to a natural bioactive substance, and compared with a chemical synthesis medicine, the egg yolk immunoglobulin is mild in component, does not easily cause strong rejection reaction of an organism, greatly reduces the occurrence probability of allergy and other adverse reactions, is also very friendly to patients with weak gastrointestinal functions, and provides a new thought for prevention and treatment of digestive tract inflammation.

A gastrointestinal implant adapted to be implanted in a gastrointestinal structure such as a duodenum, a jejunum, and / or an ileum comprises a plurality of adjacent layers bonded to one another. One of more of the layers comprises at least one of a selected pore size and interpore distance, and at least one medicament is coupled to at least one medial surface of one or more layers to achieve one or more treatment goals selected from minimizing or alleviating trauma associated with implantation of the gastrointestinal sleeve, preventing or treating infection, treating eating disorders or conditions of the patient, treating one or more gastrointestinal tract structures exterior to or distal to at least a portion of the sleeve, or treating the patient's microbiome.

The invention provides a functional feed additive for relieving clostridial enteritis of meat poultry as well as a preparation method and application of the functional feed additive. The functional feed additive is prepared from the following components in parts by weight: 30 to 50 parts of plant extract, 0.5 to 2 parts of monatomic microelement-mesoporous silicon dioxide nanoparticles, 0.1 to 2 parts of momordica saponin and 1 to 3 parts of sarcandra glabra polysaccharide. The product provided by the invention can relieve chicken intestinal structure damage caused by clostridium perfringens and protect normal structures and functions of intestinal tracts; inflammatory factors in jejunum are reduced, inflammatory response is improved, clostridium perfringens colonization is reduced, and the intestinal health level is maintained; furthermore, clostridial enteritis of meat poultry is reduced, and the production performance of broilers is improved.

The invention belongs to the technical field of natural product extraction and biological medicine preparation, and particularly relates to a jerusalem artichoke extract and application of the jerusalem artichoke extract in resisting inflammation and regulating intestinal flora and metabolites thereof. Tests prove that the jerusalem artichoke extract has the effect of relieving ulcerative colitis. Specifically, the jerusalem artichoke extract can relieve intestinal structure injury, inflammatory cell infiltration and intestinal barrier injury caused by DSS induction, and has the function of relieving ulcerative colitis. Meanwhile, the invention discloses the anti-inflammatory effect of the jerusalem artichoke extract. In addition, the jerusalem artichoke extract also has an effect of regulating intestinal flora. According to the technical scheme, the jerusalem artichoke extract obviously regulates intestinal flora disorder induced by DSS. The jerusalem artichoke extract relieves intestinal flora imbalance of DSS-induced mice, recovers a microbial community structure and regulates metabolites of the DSS-induced mice. The extraction method of the jerusalem artichoke extract is simple and low in cost, has universality and is easy for large-scale production, so that the jerusalem artichoke extract has good practical application value.

The invention relates to the technical field of intelligent medicine, in particular to a Crohn disease intestinal fibrosis condition early warning method based on large model driving, which comprises the following steps: acquiring an intestinal MRI image sequence of a Crohn disease patient; inputting the intestinal MRI image sequence into a pre-trained intestinal structure analysis large model, and positioning the position of an initial intestinal fibrosis region; determining whether the intestinal lumen stenosis degree of the patient with the Crohn disease reaches the standard or not based on the intestinal lumen stenosis progress index, and determining a feature comparison threshold value for adjusting the large model according to the difference value; determining whether the acute inflammation shielding effect of the patient with the Crohn disease is qualified or not based on the intestinal wall edema characterization parameters, and determining and adjusting the T2 weighted imaging modal weight of the large model according to the relative difference; and determining whether the fibrosis seepage channel smoothness of the patient with the Crohn disease is qualified or not based on the fibrosis seepage resistivity, and determining and adjusting the boundary loss weight of the large model according to the ratio. The early warning accuracy of the intestinal fibrosis condition of the Crohn's disease is improved.

The invention relates to application of Xpac and Det genes as biomarkers of drosophila melanogaster to nanoparticle combined cadmium pollution, which verifies the regulation effect of XPAC and Det on intestinal tract structure, DNA stability and cell apoptosis under the condition of combined pollution by knocking down the XPAC and Det genes. Results show that DNA damage is aggravated after XPAC knock-down, and Det knock-down causes serious intestinal structure damage and skeleton disintegration, which indicates that the XPAC and Det knock-down have functional differentiation in coping with combined pollution. The gene can be used as a key regulatory factor and a potential biomarker of an environmental pollution toxic reaction, and a theoretical basis is provided for pollution toxicological mechanism research and biological prevention and control strategies.

The invention relates to the technical field of microorganisms, and in particular relates to a plant lactobacillus for preparing a diarrhea postbiotic relieving plant lactobacillus and an application of the plant lactobacillus. According to the present invention, the lactobacillus plantarum is lactobacillus plantarum Mei1101.2, the preservation number is CGMCC No.30331, and the lactobacillus plantarum has characteristics of strong antibacterial activity, high yield of exopolysaccharides, good acid production performance, and good growth performance, and can be used for the production of the exopolysaccharides. According to the present invention, with the application of the phytobacterium plantarum, the diarrhea index and the excrement water content of mice can be reduced, the serum proinflammatory factor content of the mice can be reduced, the anti-inflammatory factor content can be increased, the damage of the duodenum and jejunum intestinal structures and the intestinal mucosal barrier of the mice can be improved, the intestinal flora can be adjusted, and the generation of short-chain fatty acid can be promoted; the animal diarrhea is effectively relieved.

The invention discloses application of cedrol in preparation of a medicine for treating acute ulcerative colitis, and belongs to the technical field of biological medicine. Experiments prove that cedrol can effectively improve DSS-induced colon injury, relieve inflammatory response, improve the intestinal mucosa barrier function, slow down weight loss caused by ulcerative colitis, reduce disease activity indexes, relieve the phenomena of colon shortening and loose stool and protect the structural integrity of colon; the invention provides a theoretical basis for researching and developing medicines for treating ulcerative colitis, and has wide clinical application value.

The invention discloses application of abelmoschus manihot flower polysaccharide in prevention of intestinal injury caused by ionizing radiation, and belongs to the field of prevention of radioactive intestinal injury. According to the application of the abelmoschus manihot polysaccharide in preparation of the medicine for preventing the intestinal injury caused by the ionizing radiation, the protective effect of AMP on the intestinal injury caused by 14Gy X-ray total abdominal irradiation is found by respectively carrying out ionizing radiation irradiation on mice in an irradiation control group and an irradiation + AMP group, and further experiments find that the ionizing radiation causes apoptosis of intestinal crypt cells, so that the intestinal injury caused by 14Gy X-ray total abdominal irradiation can be prevented. The regeneration capacity of the intestinal structure is destroyed, and the AMP can remarkably inhibit mouse intestinal crypt cell apoptosis induced by ionizing radiation. The invention shows the uniqueness of AMP in the protection of ionizing radiation induced intestinal injury, and has wide application prospects in the medical field.

The application discloses application of ergothioneine in preparation of products for improving growth performance, immunity, antioxidant capacity or intestinal health of fish, and belongs to the technical field of biotechnology.It is found by experiments that ergothioneine can promote growth of large yellow croaker larvae and improve muscle quality; ergothioneine can enhance immunity and antioxidant defense capacity and improve liver and intestinal health; meanwhile, ergothioneine can improve liver tissue vacuolization and intestinal villus structure and improve intestinal digestive enzyme activity; ergothioneine can regulate intestinal flora structure and intestinal metabolism; and ergothioneine can also induce systematic remodeling of liver metabolism group and transcription group.In summary, ergothioneine is a natural functional feed additive with wide application prospect, which can synergistically promote fish growth, health and quality improvement by enhancing antioxidant defense, improving liver metabolic homeostasis, maintaining intestinal structure and optimizing intestinal microecology.

The application discloses application of fuscocerine in preparation of products for relieving intestinal injury of chicks induced by salmonella, and belongs to the technical field of veterinary drugs. In a model of intestinal inflammation salmonella infected chicks, the chicks are orally administered with 20 mg / kg BW fuscocerine. The experimental results show that the fuscocerine can significantly relieve the growth performance of the chicks, improve the diarrhea condition and fecal state of the chicks, and improve the intestinal structure and permeability of the chicks through ileal M cells, thereby relieving the intestinal injury of the chicks caused by intestinal inflammation salmonella. The method for resisting intestinal inflammation salmonella of the chicks is beneficial to replacing the traditional antibiotic treatment method, and helps the development of poultry breeding.

The invention discloses an application of combination of pasteur inactivated bacteroides simplex and infliximab in preparation of a medicine for treating colitis. Firstly, compared with viable bacteria of bacteroides monoforme, the pasteurization inactivated bacteroides monoforme has more obvious effects on promoting intestinal barrier repair and inhibiting spleen enlargement, and further, experiments find that the pasteurization inactivated bacteroides monoforme can enhance the anti-inflammatory curative effect of infliximab, so that the anti-inflammatory effect of infliximab is improved, and the anti-inflammatory effect of infliximab is improved. The composition has a synergistic effect in the aspects of weight maintenance, colon structure protection and inflammation control, and has a potential application value in clinical combined treatment of inflammatory bowel diseases.

The invention discloses a Tibetan veterinary medicine composition for treating yak diarrhea as well as a preparation method and application thereof. The composition comprises Tibetan coptis chinensis, berberis poiretii schneid, fructus chebulae, dracocephalum tanguticum, polygonum viviparum, malus toringoides fruits, radix rubiae, scorched hawthorn fruits, fried malt, fructus hippophae, rhizoma zingiberis, rhizoma atractylodis, wine-treated rhubarb, oxytropis verticillata, fructus quisqualis, ligularia virgaurea, rhodiola rosea and saffron crocus. The Tibetan medicine composition provided by the invention strictly follows the principle of'three-cause balance 'of Tibetan medicine, is designed aiming at the common diseases of'red Ba' heat and'bai 'cold inclusion in plateau, and has the effects of clearing heat and drying dampness, detoxifying and stopping dysentery, tonifying spleen and warming middle-jiao, and simultaneously has multiple action mechanisms of plateau stress resistance, qi and blood regulation, parasite expelling and the like. The Tibetan medicine composition is safe and free of side effects, and can inhibit intestinal inflammation reaction, protect intestinal structure, promote nutrition digestion and absorption and enhance physique of yaks.

The invention discloses application of tussilagone in preparation of a medicine for resisting radiation injury, and belongs to the technical field of biology. The technical problem to be solved by the invention is how to resist radiation damage. The application provided by the invention specifically refers to application of tussilagone in preparation of a product for treating or / and relieving body injury caused by radiation. Experiments prove that tussilagone can effectively relieve hyperemia and bleeding and inflammatory cell infiltration of pulmonary alveoli of mice after radiation; the hepatic cord structure damage and hepatic sinus hyperemia in the hepatic tissue are relieved; disorder and vacuolation of a bone marrow structure can be relieved, and recovery of hematopoietic cells in bone marrow is promoted; edema and shedding of intestinal villi can be relieved, and the integrity of the intestinal structure can be partially repaired; and hair follicle structure damage and fiber bundle hyperplasia in skin tissues are improved.

The application relates to the technical field of intestinal sampling, in particular to a device for autonomously collecting intestinal micro-ecological samples, which comprises a colonoscope for observing the internal intestinal structure, the colonoscope comprises an outer tube for supporting the outside of the anus, an collecting head for deep observation in the intestine is slidably matched in the outer tube, and a connecting mechanism for pushing the collecting head is fixedly connected to one end of the collecting head; a sealing film for sealing the connecting mechanism is arranged on the outer side of the collecting head, and a sampling mechanism for contacting and sampling the intestinal wall outside the sealing film is arranged in the sealing film; the device is used for collecting samples at different intestinal positions, reduces the damage to the patient in the sampling process, and retains the activity and function of the bacterial flora.